Language selection

Search

Details for: XIGDUO

Company: ASTRAZENECA CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02449935XIGDUODAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE); METFORMIN HYDROCHLORIDE5 MG; 850 MGTABLETORAL
02449943XIGDUODAPAGLIFLOZIN (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE); METFORMIN HYDROCHLORIDE5 MG; 1000 MGTABLETORAL
Search Reported Side Effects Report a Side Effect

Summary Reports

Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)
Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury
Summary Safety Review - SGLT2 inhibitors - Assessing the potential risk of a rare brain condition (posterior reversible encephalopathy syndrome) in patients who have developed high levels of acids in the blood (diabetic ketoacidosis)
Summary Safety Review - Sodium/glucose cotransporter 2 (SGLT2) inhibitors - Assessing the potential risk of inflammation of the pancreas (acute and chronic pancreatitis)

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: